SU5208

CAS No. 62540-08-3

SU5208( 3-[(Thien-2-yl)methylene]-2-indolinone )

Catalog No. M22956 CAS No. 62540-08-3

SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 87 In Stock
5MG 95 In Stock
10MG 151 In Stock
25MG 238 In Stock
50MG 321 In Stock
100MG 449 In Stock
200MG 603 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SU5208
  • Note
    Research use only, not for human use.
  • Brief Description
    SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
  • Description
    SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    3-[(Thien-2-yl)methylene]-2-indolinone
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    62540-08-3
  • Formula Weight
    227.28
  • Molecular Formula
    C13H9NOS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (439.99 mM)
  • SMILES
    O=C1NC2=C(C=CC=C2)/C1=C/C3=CC=CS3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Camila Mu?oz, et al. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model. 2012 Feb;32:39-48.
molnova catalog
related products
  • Tyrphostin AG1433

    Tyrphostin AG1433 is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).

  • Pazopanib

    A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

  • Cediranib

    A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.